1022 / 1241
/ 23 22
Cost-effectiveness
Is PET-CT guided management for patients with locally advanced head and neck
squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III
randomized trial.
Smith et al., University of Leeds, J Clin Oncol 33, 2015 (suppl; abstr 6010)
Evaluation
Individual patient data evaluation for NHS reimbursement (564).
Comparison of randomized arms for 2Y cost-effectiveness.
Outcome for intervention arm
Average health benefit 0.07 QALYs
Average cost saving 1415 GBP
Probabilities at 20.000 GBP per QALY
PET/CT = cheaper
99%
PET/CT = most effective
91%
PET/CT = most cost-effective
98%